Please use this identifier to cite or link to this item:
|dc.title||Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: A microarchitectural and mechanical study|
|dc.identifier.citation||Yang, X., Chan, Y.H., Muthukumaran, P., DasDe, S., Teoh, S.-H., Lee, T. (2011-05-01). Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: A microarchitectural and mechanical study. Bone 48 (5) : 1154-1163. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bone.2011.02.007|
|dc.description.abstract||Osteoporosis remains a challenging problem. Understanding the regulation on osteoclast and osteoblast by drugs has been of great interest. Both anabolic and anti-resorptive drugs yield positive results in the treatment of osteoporosis. However, whether the concurrent administration of parathyroid hormone (1-34) and ibandronate may offer an advantage over monotherapy is still unknown. This study, therefore, attempts to compare the efficacy of two therapeutical approaches and to investigate the beneficial effects in concurrent therapy in a rat model using three-point bending, pQCT and μCT analysis. A total of 60 female Sprague-Dawley rats of age 10 to 12. weeks were divided into 5 groups (SHAM, OVX. +. VEH, OVX. +. PTH, OVX. +. IBAN, OVX. +. PTH. +. IBAN) and subjected to ovariectomy or sham surgery accordingly. Low-dose parathyroid hormone (PTH) and/or ibandronate or its vehicle were administered subcutaneously to the respective groups starting from 4th week post-surgery at weekly intervals. Three rats from each group were euthanized every 2. weeks and their tibiae were harvested. The tibiae were subjected to metaphyseal three-point bending, pQCT and μCT analysis. Serum biomarkers for both bone formation (P1NP) and resorption (CTX) were studied. A total of 11 indices showed a significant difference between SHAM and OVX. +. VEH groups, suggesting the successful establishment of osteoporosis in the rat model. Compared to the previous studies which showed impedance from bisphosphonates in combination therapy with PTH, our study revealed that ibandronate does not block the anabolic effects of PTH in ovariectomized rat tibiae. Maximum load, strength-strain indices and serum bone formation markers of OVX + PTH + IBAN group are significantly higher than both monotherapy groups. With the proper ratio of anabolic and anti-resorptive drugs, the effect could be more pronounced. © 2011 Elsevier Inc.|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.